Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 27, 2022

Primary Completion Date

August 7, 2023

Study Completion Date

January 26, 2024

Conditions
Alopecia Areata
Interventions
BIOLOGICAL

Daxdilimab

Daxdilimab will be administered subcutaneously as two injections for each dose.

Trial Locations (13)

33613

ForCare Clinical Research, Tampa

40241

DS Research, Louisville

71913

Burke Pharmaceutical Research, Hot Springs

78213

Progressive Clinical Research, P.A., San Antonio

92708

First OC Dermatology Research, Inc., Fountain Valley

99202

Dermatology Specialists of Spokane, Spokane

V3V 0C6

Enverus Medical Research, Surrey

N1L 0B7

Dr Dusan Sajic Medicine Professional Corporation, Guelph

L3P 1X3

Lynderm Research Inc., Markham

L6J 7W5

The Centre for Clinical Trials, Oakville

K9J 5K2,

SKiN Centre for Dermatology, Peterborough

H2X 2V1

Innovaderm Research, Montreal

G1W 4R4

Centre de Recherche Saint-Louis (Quebec), Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY